SF3B1 and myelodysplastic syndrome: In addition, 13% (37/300) of MDS with excess blasts (MDS-EB-1/2) and 20% (21/107) of MDS 5q- harbored SF3B1 mutations together accounting for 25% (58/231) of all SF3B1mut cases (Table 1; Fig. 1B, C).